NERCE PROJECT 9: An improved targeted vaccine strategy against anthrax -Ronald K. Taylor,Ph.D.The goal of this proposal is to initiate the development of a novel, targeted vaccine technology againstpathogens associated with bioterrorism and those that are responsible for emerging infectious diseases.Extremely rapid and potent immune responses are elicited by vaccines that target antigens specifically toprofessional antigen-presenting cells (APCs). In addition to inducing rapid and robust immune responses,targeted vaccines are potentially safer, easily administered, and require very low doses that leads to reducedcost.This project is based on a partnership between academic investigators and industry. Antigens will betargeted to dendritic cells (DCs) and other APCs using a monoclonal antibody (mAb) specific to theendocytic receptors, DEC-205 and mannose receptor (MR). These antibodies are rapidly internalized andgain access to the antigen presenting pathways. Antigens delivered in this way elicit potent antibody andcytotoxic T lymphocyte responses. Recombinant antigens will be chemically crosslinked and/or geneticallyfused to the mAbs using available human anti-DEC-205 and anti-MR gene fusion vectors.In the past year, we have fused recombinant protective antigen (rPA) of anthrax to anti-DEC-205 and testedthe ability of the fusion to elicit humoral immune responses in mice. We are proceeding to apply the samestrategy using anti-MR to develop a targeted vaccine for cholera, using recombinant TcpA from Vibriocholerae.
Showing the most recent 10 out of 417 publications
